Holen Sie sich die Stockscreener-App
1.73
2.98%
0.05
Aytu Biopharma Inc Aktie (AYTU) Neueste Nachrichten
Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For Growth - Simply Wall St
Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - AccessWire
Aytu BioPharma CEO to Present Growth Strategy at Lytham Partners Healthcare Summit - StockTitan
Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Large Growth in Short Interest - Defense World
An unknown company affiliated with Jonathan Hughes acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc.. - Marketscreener.com
Aytu BioPharma, Inc. (NASDAQ:AYTU) Is About To Turn The Corner - Simply Wall St
Aytu BioScience stock hits 52-week low at $1.4 amid market challenges - Investing.com Australia
Aytu BioScience stock hits 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa
Aytu BioPharma Announces Settlement Approval Hearing for Derivative ClaimsOn December 3, 2024, Aytu BioPharma, Inc. (NASDAQ: AYTU), a Delaware corporation, made a significant disclosure regarding the settlement of certain derivative claims in the Wi - Defense World
Aytu BioPharma Proposes Settlement in Shareholder Lawsuit - Yahoo Finance
Aytu BioPharma Reaches Settlement Agreement in Derivative Action LawsuitKey Details for Shareholders - StockTitan
Aytu BioPharma Disclosure Notification - AccessWire
Tesla CEO Elon Musk's $56B pay package rejected by Delaware judge - Yahoo Finance
Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) - AccessWire
Aytu BioPharma Makes Deloitte Fast 500 List for 4th Year, EBITDA Soars 162% | AYTU Stock News - StockTitan
Aytu BioPharma, Inc. Appoints Ryan Selhorn as Corporate Secretary and Treasurer - Marketscreener.com
Aytu BioPharma First Quarter 2025 Earnings: Beats Expectations - Simply Wall St
Aytu BioPharma Announces Fiscal 2025 First Quarter Results and CFO Transition - Defense World
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Call Transcript - Insider Monkey
Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32% - Simply Wall St
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
Aytu BioPharma Inc (AYTU) Q1 2025 Earnings Call Highlights: A Hi - GuruFocus.com
Aytu BioPharma Reports Q1 Fiscal 2025 Earnings - TipRanks
Stonepine Capital Management's Strategic Acquisition in Aytu Bio - GuruFocus.com
Aytu BioPharma Names Ryan Selhorn as CFO - MarketWatch
Aytu BioPharma Achieves First-Ever Quarterly Profit of $1.5M, Reports 72% Margins | AYTU Stock News - StockTitan
Differentiated Rx brands focused on ADHD and Pediatrics – Aytu BioPharma (NASDAQ: AYTU) | GCFF - NAI 500
Aytu BioScience stock hits 52-week low at $1.8 amid market challenges - Investing.com Australia
Vascular Ehlers-Danlos Syndrome Market on Track for Major Expansion by 2032, According to DelveInsight | Aytu BioPharma, Acer Therapeutics - The Globe and Mail
Vascular Ehlers-Danlos Syndrome Market on Track for Major - openPR
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly? - Simply Wall St
AYTU stock touches 52-week low at $1.95 amid market challenges - Investing.com Australia
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
AYTU stock touches 52-week low at $2.07 amid market challenges - Investing.com
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit - AccessWire
Aytu BioScience stock hits 52-week low at $2.2 amid market challenges - Investing.com Australia
Aytu BioScience stock hits 52-week low at $2.2 amid market challenges By Investing.com - Investing.com South Africa
Aytu BioPharma’s Exclusive Agreement with Lupin Pharma Canada Ltd - Global Legal Chronicle
Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd - Wilson Sonsini
Aytu BioPharma inks deal with Lupin for ADHD drugs in Canada - Investing.com Canada
Aytu BioPharma inks deal with Lupin for ADHD drugs in Canada By Investing.com - Investing.com South Africa
AYTUAYTU BioPharma, Inc. Latest Stock News & Market Updates - StockTitan
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada - StockTitan
0.60%
1.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):